跳至主要内容
临床试验/NCT05911776
NCT05911776已完成4 期

Nasal Packing Versus Intravenous Dexmedetomidine in Turbinate Surgeries: A Randomized Double-Blinded Trial

Kafrelsheikh University1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2023年6月30日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
60
试验地点
1
主要终点
Amount of intraoperative blood loss

研究概览

简要总结

Comparing of nasal packing DEX and IV DEX for controlling the intraoperative bleeding after turbinate surgery.

详细描述

Dexmedetomidine (DEX) is a highly selective α2 adreno-receptor agonist with higher affinity to a2 adreno-receptor than clonidine, and this makes DEX primarily sedative and anxiolytic. The elimination half-life of DEX (t1/2b) is 2 h and the redistribution half-life (t1/2a) is 6 min, and this short half-life makes it an ideal drug for intravenous titration. Potentially desirable effects include decreased requirements for other anesthetics and analgesics.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 18 to 65 years
  • Both sexes
  • American Society of Anesthesiologists (ASA) physical status classification I or II.
  • Undergo turbinate surgery

排除标准

  • Patients with a body mass index > 30 kg/m2 existing or recent significant disease.
  • Contraindications to the use of dexmedetomidine .
  • History or presence of a significant disease significant cardiovascular disease risk factors.
  • Significant coronary artery disease or any known genetic predisposition.
  • History of any kind of drug allergy,
  • Drug abuse.
  • Clinically significant abnormal findings in physical examination, electrocardiographic (ECG) or laboratory screening.
  • Known systemic disease requiring the use of anticoagulants,
  • Patients with a history of previous turbinate surgery.

研究组 & 干预措施

Group NP (nasal packing Dexmedetomidine)

Active Comparator

Patients will receive nasal packing Dexmedetomidine (1.5 μg/kg intranasal dexmedetomidine diluted with saline) and Intravenous infusion saline.

干预措施: Nasal packing Dexmedetomidine (Drug)

Group IV (Intravenous Dexmedetomidine)

Active Comparator

Patients will receive 0.5 μg/kg bolus over 10 min then 0.1- 0.4 μg/kg IV infusion Dexmedetomidine and nasal packing with saline.

干预措施: Intravenous Dexmedetomidine (Drug)

结局指标

主要结局

Amount of intraoperative blood loss

时间窗: Intraoperative up to 6hours

Measuring the volume of suctioned blood in graduated columns, which will contain an anticoagulant to prevent coagulation and clotting and weighing gauze sponges.

次要结局

  • Pain score(24 hours postoperative)
  • Quality of intraoperative surgical field(Intraoperative up to 6hours)
  • Patient's general satisfaction(24 hours postoperative)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Gamal Hendawy Shams

Lecturer of Anesthesiology, Surgical Intensive Care and Pain Medicine Faculty of Medicine Kafr-El Sheikh University

Kafrelsheikh University

研究点 (1)

Loading locations...

相似试验